Curanex Pharmaceuticals Inc. CURX on Wednesday highlighted five additional patient cases that management believes further ...
Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple ...
Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ...
Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with the ...
Morning Overview on MSN
Nanoparticle therapy targets lung tumors and cancer-related muscle loss
A team at Oregon State University has engineered lipid nanoparticles that deliver messenger RNA to lung tumors while ...
Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.
Cancer cachexia is a prevalent condition in pancreatic cancer (PC), affecting up to 80% of patients. There is an urgent need to understand this syndrome and identify potential targetable therapeutic ...
Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...
Neurons (blue) in a part of the brain called the area postrema, seen here, express a variety of genes, including receptors for the immune system molecule IL-6 (white). Cancer is insidious. Throughout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results